ASCO 2020: AZ’s Tagrisso Sails Into Early-Stage NSCLC On ‘Momentous’ ADAURA Trial Data
83% Reduction In Disease Recurrence Or Death
A highly impressive improvement in disease-free survival in ADAURA is set to pitch AstraZeneca’s best-selling product into a new untapped market, early-stage EGFRm NSCLC, reaping a possible $3bn in extra sales.
You may also be interested in...
Recently AstraZeneca became the most valuable company by market capitalization on the FTSE 100, quite a switch in fortunes from earlier in the decade, and HR head Fiona Cicconi tells Scrip that a change in culture as well as a productive pipeline has contributed to the firm's recent success.
The company stopped the Phase III ADAURA study for Tagrisso early due to overwhelming efficacy and the US FDA approved selumetinib in a rare pediatric disease.
Further competition to Sanofi/Regeneron’s Dupixent in nasal polyps is on the horizon but the newcomers will have some catching up to do.